Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study

Milan J. Sonneveld*, Shao Ming Chiu, the CREATE study group, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Bömmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus CornbergMan Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien Hung Chen, Benjamin Maasoumy

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
38 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Psychology